Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Pfizer receives FDA approval for acute myeloid leukemia therapy

The treatment also approved for children, two years and older with relapsed or refractory CD33-positive acute myeloid leukemia.
Pfizer receives FDA approval for  acute myeloid leukemia therapy
Cancer cells

Drugs titan Pfizer Inc (NYSE:PFE) shares nudged higher as it revealed the US FDA had approved its drug MYLOTARG (gemtuzumab ozogamicin) for use in adults with newly diagnosed CD33-positive acute myeloid leukemia.

The treatment was also green-lighted for adults and children, two years and older with relapsed or refractory CD33-positive  acute myeloid leukemia .

It is the first therapy with an indication that includes the children's AML and it is also the only therapy that targets CD33, an antigen expressed on cells in up to 90% of patients.

 

“Today is an important day for patients, their families and the entire AML community, as the approval of MYLOTARG brings forth a long-awaited treatment option that may lead to deeper, more durable remissions for patients with AML,” said Jorge Cortes from the Anderson Cancer Center.

 

“After many years, we are finally seeing progress in the treatment of AML, which has renewed my hope in improving outcomes for my patients. I am pleased that I can now offer many adult and pediatric patients targeted treatment with MYLOTARG.”

“The FDA approval of MYLOTARG fills a critical unmet need for many adults and children with AML, which can be fatal in a matter of months or even weeks if not treated and has a high relapse rate,” said Liz Barrett, global president, Pfizer Oncology.

“Based on clinical data, real-world experience and support from the AML community, we are grateful MYLOTARG now has the potential to help a broad range of AML patients.”

View full PFE profile View Profile

Pfizer Timeline

Article
November 23 2015

Related Articles

Summit
January 25 2018
Interim results for a study on ezutromid revealed a “statistically significant and meaningful” reduction in muscle damage, the company said
cancer cells
December 15 2017
The AIM-listed group, whose focus is cancer and autoimmune diseases, licensed its SRA737 to US firm Sierra Oncology just over a year ago
man on a ventilator
January 24 2018
The share price, 280p a year ago, has tracked the progress the firm has made in the clinic with its lead product Traumakine

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use